功能性消化不良是否需要根除幽门螺杆菌——支持的观点

幽门螺杆菌（H.pylori）阳性的功能性消化不良（FD）或非溃疡性消化不良（NUD）相当于有消化不良症状的慢性活动性胃炎，前者强调消化不良症状,后者则强调胃黏膜组织学改变。根除H.pylori可使部分患者的症状得到长期改善,胃黏膜活动性炎症消退，逆转或防止萎缩／肠化生的发展,预防胃癌和消化性溃疡，与其他治疗措施相比具有费用,疗效比优势。     

胃黏膜炎症活动度对幽门螺杆菌阳性糖尿病胃轻瘫患者的治疗影响研究

目的观察根除幽门螺杆菌（Hp）对糖尿病胃轻瘫（DGP）患者的治疗作用及胃黏膜组织学改变对疗效的影响。方法 纳入100例Hp阳性DGP患者。治疗前胃镜及病理组织学检查以了解胃黏膜炎症情况。随机分为A、B两组。A组给予莫沙比利及雷尼替丁枸橼酸铋三联根除Hp治疗。B组采用莫沙比利及雷尼替丁枸橼酸铋治疗。记录患者治疗前、治疗4周及停药4周时的症状积分。结果 92例完成实验。A组治疗4周后症状积分明显下降（P〈0.01）,与停药4周后相比差异无统计学意义（P〉0.05）,二者均明显低于B组同期（P分别〈0.05,〈0.01）。B组症状积分在治疗4周后明显下降（P〈0.01）,停药4周后明显高于治疗4周后（P〈0.05）。A组胃黏膜有活动性炎症的患者治疗4周后及停药4周后症状积分均明显低于B组（P〈0.05或0.01）。非活动性炎症患者与B组差别无统计学意义（P〉0.05）。中重度活动性炎症组停药4周后症状积分明显低于轻度组（P〈0.05）;轻度活动性炎症组及非活动性炎症组均较治疗4周后明显升高（P〈0.01）,中重度活动性炎症组症状积分无明显变化（P〉0.05）。结论 对Hp阳性的DGP患者,尤其是胃黏膜炎症活动度高者,根除Hp可明显提高疗效,并有效防止停药后症状复发。     

根除幽门螺杆菌对功能性消化不良的治疗效果观察

目的总结根除幽门螺杆菌（Hp）对Hp阳性的功能性消化不良（FD）患者的治疗作用与价值。方法将入选患者随机分为两组：对照组78例,给予奥美拉唑治疗1周;治疗组82例,给予奥美拉唑、阿莫西林、克拉霉素、胶体果胶铋等治疗1周。停药1月时对治疗组患者做14C-尿素呼气试验,根据结果将其再分为根除Hp组和根除Hp失败组。对每组患者治疗前和治疗后1月时的平均症状积分、平均治疗得分进行比较。随访12个月,比较随访期每组患者消化不良症状发生的平均天数及因本病就诊的平均医疗费用等。结果每组患者治疗前与治疗后1月时平均症状积分比较,均有显著差异（P〈0.05）：根除Hp组平均治疗得分2.77分,对照组1.01分;根除Hp失败组分0.98分;根除Hp组与其他两组比较,均有显著差异（P〈0.05）。根除Hp组随访期平均症状发生天数26.41 d,对照组50.84d,根除Hp失败组52.20 d。根除Hp组随访期平均医疗费用1 575.16元,根除Hp失败组2 992.44元,对照组2 841.37元。根除Hp组与其他两组比较差异均有统计学意义（P〈0.05）。结论根除Hp治疗对Hp阳性的FD能够明显提高治疗效果,降低医疗费用。     

老年幽门螺杆菌相关性胃炎患者抗幽门螺杆菌根除治疗前后的病理学研究

目的分析老年幽门螺杆菌（Hp）相关性胃炎患者抗Hp根除治疗前后胃黏膜病理炎症变化程度,探讨老年Hp相关性胃炎患者行抗Hp根除治疗的重要性。方法收集1989年4月至2011年6月经内镜活检病理、13C-尿素呼气试验、粪便Hp抗原检测,有长期随访资料的老年Hp相关性胃炎患者共239例,观察抗Hp根除治疗前后胃黏膜病理炎症改变程度。结果Hp彻底根除的199次治疗中,179次镜下组织学慢性炎症程度明显好转,治疗前64次有活动性炎症,治疗后27次有活动性炎症;Hp未彻底根除的66次治疗中,42次镜下组织学慢性炎症程度明显好转,治疗前39次有活动性炎症,治疗后22次有活动性炎症。Hp达根除标准的老年患者较Hp未能根除者镜下组织学慢性炎症及活动性炎症程度均明显好转（P〈0．05）。结论对老年Hp相关性胃炎患者进行抗Hp根除治疗,可明显改善患者的胃黏膜组织学慢性炎症及活动性炎症程度,有效地减少慢性胃炎的发病及减轻病变程度。     

根除幽门螺杆菌对胃黏膜癌前病变的影响的Meta分析

目的探讨根除幽门螺杆菌（Hp）对萎缩性胃炎、肠化生等癌前病变的逆转效用。方法全面检索1984年至2008年底国内外生物医学期刊发表的根除Hp对胃黏膜癌前病变影响的临床研究文献及学术会议的交流论文,共6个随机对照试验524例患者进入本系统评价。采用胃黏膜组织学评分、组织学变化作为观察指标。结果（1）Hp根除组胃黏膜萎缩程度改善率显著高于对照组（OR=0．27,95％CI0．17～0．46,P=0．000）;但胃黏膜肠化生改善率在Hp根除组和对照组之间无显著差异（OR=0．55,95％CI0．28～1．08,P=0．082）;（2）Hp根除组Hp根除后胃窦部、胃体、胃底部黏膜的活动性炎症、慢性炎症以及萎缩评分均显著低于对照组（P〈0．01）,但各部位黏膜的肠化生评分改善在Hp根除组和对照组之间无显著差异（P〉0．05）。结论本Meta分析表明,根除Hp可改善慢性萎缩性胃炎的萎缩程度,活动性炎症和慢性炎症程度,但是对胃黏膜肠化生的改善不明显。     

根除Hp感染患者胃黏膜组织学变化及胃癌患病率的随访研究

目的研究幽门螺杆菌（Hp）阳性患者根除Hp后对胃黏膜炎症、萎缩和肠上皮化生（IM）及胃癌患病率的影响。方法采用随机、对照研究方法,对在我院行胃镜检查同时行Hp及胃黏膜组织学检查者236例进行随访观察,3a后复查胃镜和组织病理学,评定组织学变化。分析Hp阳性组和阴性组在胃黏膜炎症、萎缩及IM的变化。结果Hp阳性组中胃黏膜的炎症、腺体的萎缩和肠化的总人数明显高于Hp阴性组（P〈0．05）。结论根除Hp感染可减轻胃黏膜活动性炎症、萎缩和肠上皮化生以及胃癌的发病率。     

十二指肠球部多发隆起病变与幽门螺杆菌和胃上皮化生的关系

目的探讨内镜下十二指肠球部多发隆起病变与幽门螺杆菌（Hp）感染和胃上皮化生等组织学异常关系.方法连续调查86例经胃镜检查证实十二指肠球部多发隆起病变患者,并以40例球部基本正常患者作为对照.病变组Hp阳性患者接受三联根除治疗（奥美拉唑20mg、克拉霉素250mg、甲硝唑400mg,每天2次）,疗程7 d,停药后随访6个月后复查胃镜;病变组Hp阴性者接受奥美拉唑20 mg,每天1次治疗,疗程4～6个月,停药后2周复查胃镜.比较2次胃镜检查结果,包括胃镜下隆起病变程度及球部黏膜胃上皮化生等组织学异常,分析Hp感染与上述胃镜下表现及组织学异常关系.结果对照组患者组织学仅部分发现轻度慢性炎症,未发现球部Hp感染.病变组患者Hp检出率为58.1%,胃上皮化生检出率为57.0%.Hp阳性与Hp阴性患者胃镜下隆起病变程度差异无统计学意义（P＞0.05）,但胃上皮化生检出率更高,程度更严重（P＜0.05）.76例患者复查胃镜,根除Hp或奥美拉唑治疗对Hp阳性或阴性患者球部多发隆起病变无明显作用,但根除Hp后6个月,53.6%（15/28）患者胃上皮化生消失,61.0%（25/41）患者绒毛萎缩恢复正常,所有患者淋巴滤泡完全消失（26/26）,杯状细胞减少完全恢复（25/25）,同时炎症和活动性显著减轻（P值均＜0.01）.奥美拉唑疗效不显著.结论十二指肠球部多发隆起病变患者半数以上有Hp感染.Hp感染与隆起病变伴随组织学炎症密切相关,而与其内镜下表现及严重程度无关.根除Hp可使炎症显著减轻,胃上皮化生范围缩小或消退.     

幽门螺杆菌临床研究中有争议的若干问题

幽门螺杆菌(Hp)阳性的功能性消化不良是否应根除Hp?在临床上，有时将慢性胃炎与功能性消化不良(FD)作为“同义词”，应该说两存在差异。慢性胃炎强调胃黏膜组织学改变，多数(75％～85％)病人并无消化不良症状；而FD则强调消化不良症状，部分病人可无慢性胃炎。     

根除幽门螺杆菌治疗功能性消化不良上腹痛综合征的临床疗效观察

目的 探讨根除幽门螺杆菌(Hp)对Hp阳性功能性消化不良上腹痛综合征(EPS)患者的疗效.方法 将120例Hp阳性EPS患者随机分为两组,观察组64例给予埃索美拉唑20 mg,bid;阿莫西林1.0g,bid;克拉霉素500 mg,bid三联疗法根除Hp,疗程10 d;对照组56例给予埃索美拉唑20 mg,qd常规治疗,疗程2周.治疗结束后评估患者症状改善情况.结果 疗程结束后第4周,观察组与对照组患者症状改善总有效率无明显差异(分别为87.5％和80.0％,P＞0.05);6个月后观察组症状改善总有效率明显高于对照组(分别为52.1％和29.1％,P＜0.05).结论 部分Hp阳性EPS患者根除Hp后,症状可获长期改善,因此对部分Hp阳性EPS患者根除Hp是一种有效治疗手段.     

根除幽门螺杆菌对功能性消化不良的影响

目的通过长期随访观察根除幽门螺杆菌(Helicobacterpylori,Hp)后功能性消化不良(FD)者的症状能否得到缓解,阐明Hp与FD的关系.方法60例Hp感染的FD患者参加本次研究.运用改良的Glasgow评分表对患者的症状进行评分(范围0～10分).所有病例随机分为三组抗Hp治疗.A组口服RBC(雷尼替丁枸橼酸铋)400mg、阿莫西林1g和呋喃唑酮100mg各每日2次.B组口服阿莫西林1g和呋喃唑酮100mg各每日2次.C组口服RBC400mg、克拉霉素250mg和甲硝唑400mg各每日2次.总疗程均为7d,治疗后随访2年.在治疗后第4周及随访2年后行13C-尿素呼气试验,并于随访末再次对症状评分.结果全部患者完成治疗.42例Hp得以根除,18例抗Hp治疗失败.2年后54例完成复查,6例失访.其中39例为Hp根除者(39/54).另15例为抗Hp治疗失败者,其中7例在2年中曾自行接受追加的抗Hp治疗后为阴性,8例仍Hp阳性.39例根除者中未发现复发病例.大部分的患者症状评分均有改善,但持续感染者评分高于根除者.在根除者中,平均症状评分从4.90减为2.38,差异有显著性(P＜0.05).而持续感染者从5.00减至3.00,差异无显著性(P＞0.05).结论通过长期随访,我们发现根除Hp可在较长时间内仍改善FD症状.     

Pretreatment Gastric Histology Is Helpful to Predict the Symptomatic Response After H. pylori Eradication in Patients with Nonulcer Dyspepsia

This study aimed to test whether pretreatment gastric pathology in H. pylori-infected nonulcer dyspepsia (HpNUD) patients is relevant to and predictive of the symptomatic response after H. pylori eradication. Anti-H. pylori triple therapy was administered to 250 HpNUD patients, enrolled as the therapy group. In addition, 60 patients were enrolled as the control group, in which omeprazole was an alternatives to the triple therapy. Pretreatment gastric histology was evaluated thoroughly by the updated Sydney system. A [¹³C] urea breath test was also performed to evaluate the H. pylori eradication two months and 12 months later. For each patient, the baseline, month 2, and month 12 symptom scores were assessed for the month 2 or month 12 residual symptom ratio (RSR-2m or RSR-12m), calculated from: 100% × month 2 or month 12 score/baseline score. Based on either RSR-2m or RSR-12m, patients were categorized as good response (RSR < 50%), moderate response (50–70%), and poor response (>70%) subgroups in both therapy and control groups to define the short-term and long-term symptomatic responses. Patients with successful H. pylori eradication in the therapy group showed a higher incidence of good symptomatic response (RSR < 50%) than those from the control group (month 2: 30.3 vs 12%, P < 0.05; month 12: 34.7 vs 17.1%, P < 0.05). Univariate and multivariate analysis disclosed that patients with a higher acute inflammation score (AIS) and the lowest incidence of lymphoid follicles (LF) at pretreatment gastric histology are predisposed to having a good symptom response after H. pylori eradication (P < 0.05). For HpNUD patients who have an AIS of more than three and an absence of LF at gastric histology, more than 85% had good short-term (month 2) and long-term (month 12) symptomatic relief after H. pylori eradication. In conclusion, nearly 30% of HpNUD patients can obtain symptomatic relief following H. pylori eradication. The pretreatment gastric histology of HpNUD can be helpful to monitor the symptomatic response after H. pylori eradication.     

不同幽门螺杆菌根除方案对功能性消化不良影响的临床研究

背景:功能性消化不良(FD)是常见的功能性胃肠病,幽门螺杆菌(H.pylori)是FD的重要致病因素之一。目的:探讨不同H.pylori根除方案对FD患者临床症状的疗效。方法:160例H.pylori(+)FD患者随机分为10d序贯治疗组(60例)、7d三联治疗组(60例)和对照组(40例)。所有患者于停药4周后复查~(14)C-尿素呼气试验以评估H.pylori根除率。患者于治疗前、治疗后第3、6、12个月评估FD症状。结果:10d序贯治疗组、7d三联治疗组和对照组的H.pylori根除率分别为93.2%、74.1%和48.6%(符合方案分析)以及91.7%、71.7%和42.5%(意向治疗分析),各组相比差异有统计学意义(P0.05)。治疗后第6、12个月,10d序贯治疗组和7d三联治疗组中H.pylori根除者的FD症状改善率显著高于对照组(P0.05),但两治疗组之间无明显差异。结论:10d序贯治疗和7d三联治疗的FD症状改善率无明显差异,但前者H.pylori根除率高于后者,临床可推荐10d序贯疗法治疗H.pylori(+)FD患者。     

Ranitidine bismuth citrate or omeprazole-based triple therapy for Helicobacter pylori eradication in Helicobacter pylori- infected non-ulcer dyspepsia

AIM: To test the eradication rate of Helicobacter pylori by ranitidine bismuth citrate-based triple therapy, and evaluate the symptomatic response of Helicobacter pylori eradication therapy for non-ulcer dyspepsia. METHODS: A total of 59 consecutive Helicobacter pylori infected non-ulcer dyspepsia patients were randomly selected to receive either one of two triple therapy regimens, including metronidazole, amoxycillin plus ranitidine bismuth citrate (RAM group) or omeprazole (OAM group). To determine the success of eradication, patients underwent the 13C-urea breath test, 6 weeks and one year after treatment. The dyspeptic symptom scores were also assessed at the time of enrolment, 6 weeks and one year after treatment. RESULTS: Per-protocol and intention-to-treat eradication rates were 77.7% and 70% in RAM group and 83.8% and 68.9% in OAM group (p = non significant). At both the 6th week and at the first year after treatment, the mean symptom scores were lower than pre-treatment scores in the study population, regardless of whether treatment was successful or not. However, patients, whether eradicated successfully or not-eradicated, presented similar 6-week and 1-year scores. CONCLUSIONS: One-week RAM triple therapy, which is cheaper than the OAM regimen, is a relatively effective alternative regimen for Helicobacter pylori eradication in Taiwanese. Triple therapy for Helicobacter pylori eradication was not the whole management for the relief of dyspeptic symptoms of non-ulcer dyspepsia patients.     

Functional dyspepsia, H. pylori and post infectious FD

BACKGROUND: Functional dyspepsia has been defined by Rome III as the presence of one or more chronic dyspepsia symptoms in the absence of any organic, systemic, or metabolic disease that is likely to explain the symptoms. Delayed gastric emptying, antral hypomotility and altered intestinal motility, decreased gastric accommodation, H.pylori infection, enhanced visceral sensitivity, abnormal duodenal sensitivity to acid, carbohydrate maldigestion and psychological factors have all been identified in subgroups of patients with functional dyspepsia. RELATIONSHIP BETWEEN H.PYLORI, FD AND POST INFECTIOUS FD: The relationship between H. pylori infection and functional dyspepsia is controversial. H.pylori infection is present in a minority of patients with FD. Symptoms and abnormalities of function such as gastric emptying have not been consistently shown to be related to H.pylori infection. However, meta-analysis has shown that H.pylori eradication therapy in FD results in a small but statistically significant effect in H.pylori positive FD (relative risk reduction 10%). Guidelines for Helicobacter pylori infection have therefore strongly recommended H.pylori eradication therapy in H.pylori positive FD patients. Post-infectious dyspepsia has been described as a distinct clinical entity, based on a large retrospective study that showed a subset of dyspeptic patients who had a history suggestive of post-infectious dyspepsia. In a prospective study, investigators in Spain have found that development of dyspepsia was increased fivefold at 1 year after acute Salmonella gastroenteritis. In post-infectious FD patients, early satiety, weight loss, nausea, and vomiting are frequently reported together with a higher prevalence of impaired gastric accommodation. More recently, infectious FD has been found to be associated with persisting focal T-cell aggregates, decreased CD4+ cells and increased macrophage counts in the duodenum for several moths after acute infection. This suggests impaired ability of the immune system to terminate the inflammatory response after acute insult. CONCLUSION: In conclusion, H. pylori infections, as well as other gut infections, have been associated with a subset of FD patients. Treatment of underlying infections can potentially lead to improvement in this group of patients.     

Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease

OBJECTIVES: Eradication of Helicobacter pylori (H. pylori) infection markedly reduces the recurrence of duodenal and gastric ulcers. However, there is little information regarding its efficacy in resolving dyspeptic symptoms in ulcer patients. The primary aim of this study was to assess the effect of eradicating H. pylori infection on dyspeptic symptoms in ulcer patients. The secondary aim was to identify predictors of symptomatic response to H. pylori eradication. METHODS: A total of 97 dyspeptic patients with active duodenal and/or gastric ulceration associated with H. pylori infection and unrelated to NSAID use had the severity and character of their dyspeptic symptoms measured before and again 1-3 yr after H. pylori eradication therapy. RESULTS: Pretreatment, the median dyspepsia score was 12 (4-16). Posttreatment, 55% of those eradicated of H. pylori had resolution of dyspepsia (score <2) compared with 18% of those not eradicated of the infection (95% CI for difference, 11-62%). Of the ulcer patients 31% had symptoms and/or endoscopic evidence of coexisting gastroesophageal reflux disease (GERD) at initial presentation and this influenced the symptomatic response to eradication of H. pylori. Of the 22 patients with heartburn or acid reflux as the predominant presenting symptom, but no endoscopic esophagitis, only 27% experienced resolution of dyspepsia after H. pylori eradication, compared with 68% of the 59 without those as predominant symptoms (95% CI for difference, 18-63%). Only one of the five patients with coexisting endoscopic esophagitis at initial presentation experienced resolution of dyspepsia after H. pylori eradication. Symptomatic benefit was unrelated to time lapsed since the infection was eradicated. Only three of 50 subjects developed de novo GERD symptoms after eradication of H. pylori, whereas 21 of 36 subjects experienced resolution of GERD symptoms after eradication of the infection. CONCLUSIONS: A substantial proportion of ulcer patients have symptoms and/or signs of coexisting GERD at initial presentation and this reduces the symptomatic benefit from H. pylori eradication. However, we have found no evidence that eradicating H. pylori induces de novo GERD symptoms in ulcer patients.     

Role of anti-secretory treatment in addition to Helicobacter pylori eradication triple therapy in the treatment of peptic ulcer]

BACKGROUND/AIMS: It is not clear whether the anti-secretory therapy should be continued for symptomatic relief and ulcer healing before or after the eradication of H. pylori in patients with peptic ulcer disease. The aim of this study was to evaluate the effectiveness of additional anti-secretory therapy before or after H. pylori eradication in peptic ulcer disease. METHODS: Thirty eight patients with H. pylori-positive active peptic ulcer were included. Patients were randomly allocated into 3 groups; standard 1-week triple therapy followed by omeprazole (20 mg, qd) for 3 weeks (group A), standard 1-week triple therapy only (group B), and omeprazole (20 mg, qd) for 3 weeks followed by 1-week triple therapy (group C). Endoscopy with the rapid urease test and histology for H. pylori was performed 4-8 weeks after the completion of treatment. The symptom was scored by a visual analog scale. RESULTS: Of the 38 patients, 10 were excluded from the per-protocol analysis of this study. The H. pylori eradication rates were 87.5% (group A), 80.0% (group B) and 90.0% (group C) respectively. The peptic ulcer healing rates were 100% in group A, 70.0% in group B, and 90.0% in group C. There was no difference in H. pylori eradication rates and ulcer healing rates among three groups (p>0.05). Symptom score differences between pre-treatment and post-treatment group were not significantly different (p>0.05). CONCLUSIONS: The standard one week triple therapy with or without 3-weeks anti-secretory treatment with omeprazole before or after the therapy does not affect H. pylori eradication rates, peptic ulcer healing rates, and symptom score improvement.     

Prevalence of Gastric Myoelectrical Abnormalities in Patients with Nonulcer Dyspepsia and H. pylori Infection

The aims of this study were to investigate the effects of H. pylori eradication on gastric myoelectrical activity and dyspeptic symptoms. Sixty-two subjects with H. pylori infection and no active peptic ulcer participated in this study, which involved three sessions. Anti-H. pylori therapy consisting of clarithromycin and omeprazole was given for two weeks. Gastric myoelectrical activity was measured using surface electrogastrography and dyspeptic symptoms were scored at each session. A [¹⁴C] urea breath test was performed at baseline and one month after treatment. In comparison with baseline, the percentage of normal slow waves was significantly increased and the mean total symptom score was significantly reduced one and three months after therapy (P < 0.05). Approximately 40% of patients with nonulcer dyspepsia symptoms and H. pylori infection have abnormal gastric myoelectrical activity, which may be normalized following the eradication of H. pylori infection. The normalization of gastric myoelectrical activity may be one explanation for the significant symptom improvement in this subset of the dyspepsia population after H. pylori eradication.     

根除幽门螺杆菌对功能性消化不良疗效的研究

背景:功能性消化不良(FD)的患病率始终居高不下,目前就幽门螺杆菌(H.pylori)阳性的FD患者是否需根除H.pylori尚存在争议。目的:探讨根除H.pylori对H.pylori阳性FD患者的疗效。方法:200例H.pylori阳性FD患者随机分为治疗组(100例.予以枸橼酸铋雷尼替丁400mg+阿莫西林1000mg+克拉霉素250mg,2次/d,疗程1周)和对照组(100例,予以铝碳酸镁1000mg,3次/d,疗程1周)。随访结束后评估H.pylori根除率和FD症状改善情况。结果:治疗组的H.pylori根除率分别为87.5%(PP分析)和84.0%(ITT分析),对照组H.pylori根除率为0%。H.pylori根除亚组FD症状改善的总有效率显著高于H.pylori未根除亚组和对照组(90.5%对41.7%和45.9%,P0.01)。结论:部分H.pylori阳性FD患者根除H.pylori后,其症状可长期缓解,因此对部分H.pylori阳性FD患者根除H.pylori是一种值得推广的有效治疗手段。     

Can Helicobacter pylori-associated dyspepsia be categorized as functional dyspepsia?

Evidence for an association between H. pylori and functional dyspepsia (FD) is uncertain. In the present review, we focused the special relevance of H. pylori infection to the development dyspepsia from the aspects of pathogenesis, clinical efficacy of eradication of H. pylori in the West and in the East. Although clinical trials conducted to evaluate the efficacy of H. pylori eradication treatment for FD, including non-ulcer dyspepsia (NUD), have yielded conflicting results, it is quite clear that H. pylori eradication treatment is effective at least in a subset of FD patients. In contrast to the previous results obtained in studies of Western populations, the result of a double-blind, randomized, placebo-controlled trial conducted in a Singapore suggests that patients with FD could benefit from H. pylori eradication therapy, with as much as a 13-fold increase in the chance of symptom resolution. Especially in Asia, H. pylori should not be overlooked when considering the pathophysiology of FD. H. pylori-associated dyspepsia might be dealt as a different disease entity from FD.     

功能性消化不良与幽门螺杆菌根除治疗

幽门螺杆菌（H．pylori）阳性功能性消化不良（FD）或非溃疡性消化不良（NUD）患者几乎均有慢性和（或）急性活动性炎症的组织学改变，使FD与慢性胃炎的鉴别更为闲难．亦影响了FD患者根除H．pyZo一治疗的研究。罗马Ⅲ诊断标准是以症状学为主的诊断标准，FD仅发生于具有心理调节障碍的特殊易感群体，患者存在中枢神经系统的高敏感性、脑-肠轴调控功能异常以及某些神经介质和神经肽类物质分泌异常．并显示有遗传特征。根除Hpylori可能对部分H．pylori阳性FD患者有益，在仔细评估患者利益和风险的情况下．可考虑对FD患者行根除H．pylori治疗。